ArticleAlzheimer's & dementia (Amsterdam, Netherlands)
Metabolic and renal factors associated with plasma phosphorylated tau analytes used to detect Alzheimer's disease pathology.
Article in Alzheimer's & dementia (Amsterdam, Netherlands). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Peripheral Syndecan-3 and Neurofilament Light Chain as Complementary Blood Biomarkers for Alzheimer's Disease.International journal of molecular sciences · 2026Article
- Translating blood-based biomarkers into Alzheimer's disease clinical practice: screening, diagnosis, and longitudinal monitoring.Frontiers in aging neuroscience · 2026Review
Corrections and comments
- Update of
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: We examined the extent to which insulin resistance (IR), type 2 diabetes mellitus, obesity, and kidney function are associated with plasma phosphorylated tau (p-tau) concentrations (p-tau181, p-tau217, p-tau231) in the same cohort and the contribution of these factors on amyloid positron emission tomography (PET) concordance and longitudinal p-tau levels. Methods: We analyzed data from 287 participants using partial Spearman rho, Mann-Whitney Results: Concordance between plasma p-tau217 and amyloid PET was not influenced by IR or estimated glomerular filtration rate (eGFR). Accounting for eGFR improved concordance of p-tau181 and p-tau231 with amyloid PET. Age, binarized waist-to-hip ratio, and amyloid status were associated with all longitudinal p-tau concentrations, and eGFR associated with longitudinal p-tau231. Discussion: Metabolic factors may influence the interpretation of longitudinal plasma p-tau concentrations and kidney function may influence amyloid PET concordance for p-tau181 and p-tau231, potentially necessitating analyte-specific adjustments or considerations in clinical interpretation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.